Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Wilms Tumor 1Multiple Myeloma 1Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Congenital Abnormalities 1

Interventions

Cytarabine 26Daunorubicin 11Mitoxantrone 7Idarubicin 7Etoposide 7fludarabine phosphate 6Filgrastim 6Busulfan 6Tacrolimus 5Peripheral Blood Stem Cell Transplantation 5Methotrexate 5Gemtuzumab 5Clofarabine 5tipifarnib 4alvocidib 4Vorinostat 4Decitabine 4Azacitidine 4sargramostim 3Whole-Body Irradiation 3Observation 3Mycophenolic Acid 3Granulocyte Colony-Stimulating Factor 3Bortezomib 3Biopsy 3Antilymphocyte Serum 3entinostat 2Sirolimus 2Pravastatin 2Flow Cytometry 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Leukemia, Myelomonocytic, Acute × Proteasome Inhibitors × Clear all
NCT02030405 2019-04-05

Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Stanford University

Phase 2 Terminated
4 enrolled 10 charts
Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡